FG001 lighted up lung cancer in 5 out of 7 patients Optimal dose and time of administration to be established We expect the share to trade up ~10% today
Pushes and pulls in Biden’s Inflation Reduction Act 2022 Max impact ’26–early ’30s, possible mitigations thereafter Negative but manageable for AZN, biotech largely spared
Lights up in 11/11 new patients & confirmatory histology Enables it to proceed with phase 2 component… ... enabling potential efficacy readout in Q3’22e
Hospital activity levels are reaching new highs Expectations are generally too low for Q1 and FY’22 Medtech valuations down 33% YTD with better prospects
Developer of dyes that improve outcomes in cancer surgery New standard in a >DKK 3bn niche market opportunity Trigger-heavy 2022; BUY, TP of SEK 132, 50% upside